The majority of breast cancer models for drug discovery are based on orthotopic or subcutaneous tumours. Therapeutic responses of metastases, especially microscopic metastases, are likely to differ from these tumours due to distinct cancer-microenvironment crosstalk in distant organs. Here, to recapitulate such differences, we established an ex vivo bone metastasis model, termed bone-in-culture array or BICA, by fragmenting mouse bones preloaded with breast cancer cells via intra-iliac artery injection. Cancer cells in BICA maintain features of in vivo bone micrometastases regarding the microenvironmental niche, gene expression profile, metastatic growth kinetics and therapeutic responses. Through a proof-of-principle drug screening using BICA, we found that danusertib, an inhibitor of the Aurora kinase family, preferentially inhibits bone micrometastases. In contrast, certain histone methyltransferase inhibitors stimulate metastatic outgrowth of indolent cancer cells, specifically in the bone. Thus, BICA can be used to investigate mechanisms involved in bone colonization and to rapidly test drug efficacies on bone micrometastases.
In the clinic, primary breast tumours are usually surgically removed soon after diagnosis, leaving patients ‘tumour-free’. However, 20–40% of breast cancer survivors will eventually suffer metastasis to distant organs, sometimes years after surgery1,2. Thus, the life-threatening enemy is typically not the bulk of primary tumours, but the dispersed metastatic seeds, which have disseminated to distant organs, may be temporarily dormant, and may resume aggressive outgrowth under certain yet-to-be-identified conditions. Current adjuvant therapies are intended to eliminate these cells. However, the therapeutic decisions and strategies are usually based on pathological features of primary tumours. Metastases are likely to differ from their parental primary tumours due to Darwinian selection and/or adaptation in a different milieu. In either case, the microenvironment in distant organs plays a critical role in driving the selection and/or adaptation of cancer cells.
Bone is the organ most frequently affected by breast cancer metastasis3,4,5,6,7. Its diagnosis relies on skeletal-related events, including pathological fractures8. Mechanistically, these events are caused by the vicious cycle between osteoclasts and cancer cells4,9. Cancer cells can release factors such as parathyroid hormone-related protein, which will stimulate the production of Receptor activator of nuclear factor kappa-B ligand (RANKL) by osteoblasts, leading to the activation of osteoclasts9,10,11. Reciprocally, growth factors such as insulin-like growth factor-1 and transforming growth factor-β are released from dissolved bone matrix to further fuel cancer cell growth9,12.
We have recently provided evidence supporting a pre-osteolytic phase of bone colonization before the vicious cycle13. In this phase, breast cancer cells, especially the luminal subtype, tightly interact with cells in the osteoblast lineage, or osteogenic cells. Osteoclasts, on the other hand, do not appear to be involved until the transition from ‘osteogenic’ lesions to ‘osteolytic’ lesions. Consistent with this finding, cancer cells injected through the iliac artery soon became tightly embedded in bone tissues and could only be dissociated with protease digestion, even after bone fragmentation14. This characteristic led us to establish an ex vivo model named ‘bone-in-culture array’ or BICA. Here we provide evidence demonstrating that BICA mimics cancer–bone interactions in the pre-osteolytic phase, and also recapitulates transitions to the osteolytic phase. Thus, it represents a preclinical platform that may fill the gap between in vitro and in vivo models, and accelerate mechanistic and pharmacological studies of bone metastasis.
BICA provides a bone-like microenvironment
BICA is based on a technique that we have previously established, namely intra-iliac artery (IIA) injection13, which selectively delivers cancer cells into the hindlimbs of mice through arterial circulation. After injection, cancer cells usually home to the spongy bone of the tibia or femur bones. To develop BICA, we extracted and fragmented epiphysis and metaphysis of hindlimb bones containing the cancer cells (Fig. 1a and Supplementary Fig. 1a). The bone fragments (0.5–1.5 mm in diameter and 0.2–0.4 g cm−3 in mineral density; Supplementary Fig. 1b,c) can be maintained in tissue culture for up to 6 weeks without significant loss of viability (Supplementary Fig. 1d). Since the breast cancer cells utilized in this study are engineered to express luciferase, bioluminescence imaging can be used to quantify viable cancer cells. Cancer cells remain confined within fragments during this time, probably due to the tight interaction between cancer and bone cells (Fig. 1a). About 20–50 bone fragments can be obtained from one mouse, thus greatly reducing the number of mice needed for each experiment and making multiple parallel applications feasible. In the following paragraphs of this section, we describe several experiments performed to compare BICA with in vivo bone lesions (IVBL) introduced by IIA injection. In these comparisons, we also included orthotopic tumours and cancer cells maintained in two-dimensional (2D) cultures to represent the non-bone microenvironment.
To determine whether the microenvironment of cancer cells in BICA and IVBL are similar, we performed immunofluorescent staining of alkaline phosphatase (ALP), collagen I (Col-I) and cathepsin K (CTSK). ALP and Col-I are expressed in the cells of the osteoblast lineage, whereas CTSK is a marker of activated osteoclasts. The expression pattern of these molecules is very similar in the two models (Fig. 1b and Supplementary Fig. 1e), and consistent with what we have previously found in bone micrometastases at the pre-osteolytic stage13.
Peri-vascular niche has been increasingly implicated in regulating cellular fates of disseminated tumour cells. We examined whether endothelial cells remain in BICA. Indeed, immunofluorescence staining of CD31+ cells uncovered that at least some of these cells can persist for up to 3 weeks in BICA (Supplementary Fig. 1f), providing potential opportunities to study the interaction between cancer cells and the peri-vascular niche.
Although activated osteoclasts are absent at early time points, we noticed that some monocytes, the precursors of osteoclasts, remain close to bone fragments in BICA (Fig. 1c). To test whether these monocytes still maintain the potential to differentiate into osteoclasts, we added macrophage colony-stimulating factor (M-CSF) and RANKL to the medium and performed staining of tartrate-resistant acid phosphatase (TRAP) to examine osteoclastic activities. Indeed, M-CSF/RANKL treatment induced TRAP+, multinuclear osteoclasts (Supplementary Fig. 2a) indicating that monocytes in BICA retain differentiation abilities. To ask whether monocytes can spontaneously differentiate into activated osteoclasts in BICA, we applied cancer cell models that rapidly induce osteolytic vicious cycle in vivo, namely MDA-MB-231 cells and one of its osteotropic subpopulations, SCP28 cells15. At relatively late time points (3–5 weeks), we examined osteoclast differentiation by CTSK or TRAP staining. As expected, these cancer cells induced spontaneous osteoclastogenesis in BICA, both to monocytes suspended in medium (Supplementary Fig. 2b) and to those remaining in bone fragments (Fig. 1d and Supplementary Fig. 2c). In contrast, cancer cells that undergo indolent metastatic growth and prolonged pre-osteolytic stage (MCF-7) did not exhibit the same activity (Supplementary Fig. 2b,c). The activated osteoclasts in BICA appear to dissolve bone matrix as evidenced by an increased surface-to-volume ratio in SCP28-containing bone fragments (Supplementary Fig. 2d). Moreover, SCP28 cells showed a similar growth kinetic to in vivo condition and grew more rapidly as compared to the parental MDA-MB-231 cells in early time points, confirming that BICA can recapitulate metastasis bone tropism (Supplementary Fig. 2e). The growth kinetics of SCP28 cells in BICA closely mimicked the same cells in IVBL till 4 weeks after injection (Supplementary Fig. 2f), when tumour-induced osteoclastogenesis had already started. However, the growth then became retarded, probably because the tumour burden had saturated the bone surface area in the fragments. Thus, BICA may not be able to recapitulate full-fledged vicious cycle. Despite this limitation, our data demonstrated the suitability of BICA in modelling pre-osteolytic stage and perhaps also the transition from pre-osteolytic to osteolytic stages during bone colonization.
To further characterize BICA at a molecular level, we performed transcriptomic profiling to determine similarities or differences between BICA and IVBL. Cancer-containing bone segments in both BICA and IVBL were subjected to RNA-seq along with 2D culture samples and orthotopic tumours. Since we used MCF-7 cells as a proof of principle, the cancer cell and host transcriptomes are human and mouse, respectively, and can be separated by mapping them to different reference genomes (Supplementary Fig. 3). We first applied CIBERSORT16 to the mouse sequences to deduce cell types constituting the microenvironments of BICA, IVBL and orthotopic tumours. The major cellular components are comparable between BICA and IVBL, both of which differ markedly from those in orthotopic tumours. Importantly, among the 13 major cell types included into the analysis, osteoblasts, osteoprogenitors and mesenchymal stem cells together account for over two-thirds of microenvironment cells in both BICA and IVBL, but not in orthotopic tumours (Fig. 1e). These data support our previous finding that the niche of early-stage bone colonization is predominantly osteogenic13. Principle component analysis and t-Distributed Stochastic Neighbor Embedding analysis17 of human RNAs indicated that the transcriptomic profiles of cancer cells in BICA more closely mimic those in IVBL, as compared to cancer cells in 2D and in orthotopic tumours (Fig. 1f). Taken together, these results provide additional evidence supporting BICA as a platform to mimic the bone microenvironment.
BICA provides opportunities to study metastasis dormancy
Some indolent cancer cells undergo delayed growth after being introduced into the bone by IIA injection13, suggesting a period of dormancy. To track cellular fates of cancer cells in different microenvironment, we used inducible expression of histone protein 2B (H2B) fused with either firefly luciferase (Fluc) or green fluorescent protein (GFP). Similar systems were used before to study quiescent adult stem cells18. When the expression of H2B-Fluc/GFP was fully induced in all cells, we withdrew doxycycline and followed GFP or bioluminescence signals. We expected quiescent cells would maintain the expression of the fusion proteins in nucleus. Proliferating cells would have the fusion proteins diluted in each cell, but the overall quantity of the proteins should maintain the same level. Cell death would cause a net loss of these proteins. We validated these predictions in 2D cultures by immunofluorescence staining of GFP in conjunction with Ki67 or BAX to indicate proliferation and apoptosis, respectively (Fig. 2a). We chose BAX as an apoptosis marker here because Cleaved Caspase 3 is absent in MCF-7 (ref. 19). In parallel, we also used constitutive expression of Fluc/GFP to simply follow numbers of viable cancer cells (Fig. 2a). The combination of constitutive and inducible systems allowed us to delineate cancer cell fates: if a cell population is mainly consists of proliferating and dying cells, one would expect to see an alteration of constitutive Fluc/GFP (depending on the balance between proliferation and cell death), but a net decrease of induced H2B-Fluc/GFP signals. On the contrary, dormant cell population would have stable signals in both settings.
When this strategy was applied to MCF-7 cells, we found that constitutive Fluc/GFP exhibited delayed increase in both IVBL and BICA samples for about 2 weeks. In contrast, this signal immediately entered exponential growth in 2D cultures and on introduction to mammary fat pads (Fig. 2b). Cancer cells cultured under several other conditions also failed to mimic the growth kinetics of IVBL, including those growing on plates coated with specific extracellular proteins, in three-dimensional (3D) suspension medium, or directly dropped on top of bone fragments (instead of getting incorporated via IIA injection; Supplementary Fig. 4a–c). In parallel, the induced H2B-Fluc signal of MCF-7 cells was stable for 2 weeks in BICA before starting to decrease, whereas the same signal in 2D cultures rapidly decreased (Fig. 2c). Immunofluorescence staining confirmed that cancer cells in BICA maintained expression of H2B-GFP and were negative for both Ki67 and BAX (Fig. 2d). Since endothelial cells persist in BICA (Supplementary Fig. 1f), we asked whether dormant cancer cells localize to peri-vascular niche20,21. Indeed, as reported in the previous literature21, we detected indolent MDA-MB-231 cells adjacent to CD31+ cells (Supplementary Fig. 4d), supporting the significance of this niche. Taken together, these data strongly suggest that some indolent cancer cells undergo a short period of dormancy in BICA, providing an opportunity to study the underlying mechanisms.
BICA recapitulates the osteogenic niche
We asked whether the cancer–niche interaction in BICA mimics that of IVBL. Analyses of the RNA-seq results revealed that cancer cells in both BICA and IVBL exhibited increased expression of mTOR target genes as well as genes involved in cell–cell adhesions (Fig. 3a). This is consistent with our previous studies showing that luminal breast cancer cells utilize E-cadherin to form heterotypic adherens junctions with N-cadherin expressed by osteogenic cells13. This interaction activates the mTOR pathway in cancer cells and drives metastatic progression during early-stage bone colonization13 (Fig. 3b). In the following experiments, we asked whether BICA could recapitulate the cancer–niche interaction observed in whole animals by pharmacological or genetic perturbations of the heterotypic adherens junctions–mTOR pathway in both BICA and IVBL.
First, we conditionally knocked out N-cadherin in osteogenic cells or endothelial/haematopoietic cells using Osterix-cre or Tie2-cre alleles in combination with Cdh2flox (encoding N-Cadherin) alleles, respectively (Fig. 3c and Supplementary Fig. 5a). Bone colonization of syngeneic AT3 cells was significantly impaired in Osterix-cre;Cdh2f/f animals, as compared to control animals and Tie2-cre;Cdh2f/f (Fig. 3d and Supplementary Fig. 5b). A similar reduction in tumour growth in BICA was also observed using these mouse strains as sources for bone fragments (Fig. 3e and Supplementary Fig. 5c), suggesting that N-cadherin is important for cancer colonization both in IVBL and in BICA.
Second, we tested the efficacies of an mTOR inhibitor (Torin 1), a mitogen-activated protein kinase (MAPK) inhibitor (PD98059) and a neutralizing antibody against E-cadherin on cancer cells in BICA, IVBL or 2D cultures. Both the mTOR inhibitor and anti-E-cadherin treatment significantly inhibited the progression of IVBL (Fig. 3f,g), as expected based on our previous findings (Fig. 3b)13. On the other hand, the MAPK inhibitor failed to affect bone colonization (Fig. 3h). When applied to BICA, both the mTOR inhibitor and anti-E-cadherin treatment could similarly inhibit cancer cells with high efficiencies (Fig. 3i,j). Importantly, the efficacy of anti-E-cadherin treatment is higher in BICA as compared to 2D cultures (Fig. 3j), indicating that BICA enhances sensitivity of cancer cells to E-cadherin blockade. In contrast, BICA confers resistance to the MAPK inhibitor, a phenomenon also seen in IVBL (Fig. 3h) but not in 2D culture (Fig. 3k).
Thus, BICA, similar to IVBL but different from 2D cultures, exhibited expected responses to various molecular perturbations based on our understanding of the osteogenic niche. These data support the reliability of BICA as a model to recapitulate cancer–niche interaction in the bone.
Multiple parallel drug tests using BICA
As a proof of principle, we chose a small library of chemical compounds and tested their effects on cancer cells in BICA. The library contains 68 small-molecule epigenetic modulators (designated as EG library, available from Selleckchem, Catalogue # L1900). This was chosen based on the rationale that adaptation of cancer cells to the bone microenvironment may involve epigenomic reprogramming, which might be modulated by some of these compounds. For comparison, we simultaneously applied these compounds to the same cancer cells in 2D cultures. We intended to identify compounds exhibiting differential effects in BICA as compared to 2D cultures.
Two rounds of tests were conducted. In the first round, the EG library was divided into functionally related groups containing five to six compounds (Supplementary Table 1). Groups that exhibited strong effects were then separated and subjected to the second-round tests (Fig. 4a). In the first round of tests, diverse effects of different groups were observed in both BICA and 2D cultures (Fig. 4b). In particular, we noticed that Aurora kinase inhibitors and histone methyltransferase (HMT) inhibitors exhibited significant but opposite effects: the former inhibited and the latter stimulated tumour growth in BICA, as compared to the same cancer cells in 2D cultures (Fig. 4b). Histone deacetylase inhibitors also exhibited strong anti-tumour effects in both 2D cultures and BICA. However, a toxicity test using tumour-free bone fragments revealed strong negative impacts of these compounds on the viability of healthy bone cells (Supplementary Fig. 6). Therefore, we only focused on the Aurora kinase inhibitors and HMT inhibitors. The second round of tests identified danusertib as an individual drug responsible for the inhibitory effects seen for the Aurora kinase inhibitors (Fig. 4c), and EPZ-6438 and MM-102 for the stimulatory effects of the HMT inhibitor group (Fig. 4d). These drugs did not affect the viability of tumour-free bone segments when used at the same dosage (Supplementary Fig. 6). Therefore, we chose to focus on danusertib, EPZ-6438 and MM-102 for further analyses.
Danusertib preferentially eliminated cancer cells in bone
Aurora kinases play an important role in regulation of mitosis and cell proliferation22. They have recently been implicated in epigenetic modification of histones. Danusertib is a pan-Aurora kinase inhibitor23, and has been tested in phase 2 clinical trials24. Here our results pointed to an increased efficacy of danusertib on cancer cells in BICA as compared to those in 2D cultures (Fig. 5a). Specifically, 100 nM danusertib could achieve over 90% inhibition rate of tumour growth in BICA, but only ∼60% in 2D or 3D cultures (Fig. 5a and Supplementary Fig. 7a,b). This difference is unlikely due to different levels of baseline proliferation, as the proliferation rate in 3D suspension medium is much lower than that in 2D or BICA, yet the inhibition rate of danusertib in 3D culture is similar to that in 2D culture, but lower than that in BICA (Supplementary Fig. 7b). Thus, the bone microenvironment appears to enhance sensitivity of cancer cells to danusertib.
We sought to validate this increased sensitivity in additional cancer models. To this end we examined MDA-MB-361, another cancer cell line that can slowly colonize bone. We also tested a patient-derived xenograft (PDX) model using BICA. In both cases, danusertib exhibited similar inhibitory effects as with MCF-7 cells (Fig. 5b,c).
We next tested the efficacy of danusertib in vivo. We were especially interested in examining the effects of danusertib on early-stage, microscopic bone metastases. Therefore, we chose to use indolent models with a prolonged pre-osteolytic stage. The bone colonization kinetics of MCF-7 cells were characterized in our previous studies. The osteolytic vicious cycle typically occurs over 5 weeks after IIA injection13, providing a time window to examine drug effects in the pre-osteolytic stage. Treatment with danusertib almost completely abolished the progression of pre-osteolytic bone lesions (Fig. 5d and Supplementary Fig. 7c). The same dosage of danusertib also reduced orthotopic tumour growth, although to a lesser degree as compared to the reduction of bone colonization (Supplementary Fig. 7d).
To further validate the efficacy of danusertib on spontaneous bone metastases, we used 4T1.2 cell line as a model25. When transplanted into the mammary glands of syngeneic Balb/c mice, 4T1.2 cells can give rise to orthotopic tumours that spontaneously disseminate to other organs, including bone. We removed the orthotopic tumours when they reached 0.5 cm3 and monitored metastases to various organs. Danusertib treatment was initiated after orthotopic tumour removal. The ‘adjuvant’ danusertib treatment significantly reduced spontaneous bone metastases (Fig. 5e), but not local recurrences of orthotopic tumours (Supplementary Fig. 7e).
Finally, we asked whether danusertib inhibits bone colonization by eliminating dormant cancer cells, which would be highly desirable in the clinic to permanently decrease risks of recurrence. Towards this end, we used the inducible H2B-Fluc/GFP system and found that danusertib decreased the otherwise stable H2B-Fluc/GFP signals in BICA, a strong indication of reduction of dormant cancer cells (Fig. 5f and Supplementary Fig. 7f). This was supported by the BAX expression observed in H2B-GFP+ cells in danusertib-treated bone fragments (Fig. 5g).
Taken together, these data support that danusertib treatment represents an effective strategy to prevent bone recurrences, possibly by eliminating dormant disseminated tumour cells in the bone.
EPZ-6438 and MM-102 stimulate tumour progression in bone
EPZ-6438 targets EZH2 (ref. 26), and MM-102 is a potent WDR5/MLL interaction inhibitor27. Both of these compounds stimulated tumour growth in BICA. Moreover, this stimulatory effect was BICA-specific (Fig. 4d and Supplementary Fig. 7b). In 2D cultures, these two compounds had modest inhibitory effects on cancer cell viability at a dosage of 10 μM (35% inhibition for EPZ-6438 and 13% inhibition for MM-102). However, a clear dose-dependent increase of tumour burden was seen when applied to BICA (Fig. 6a). The same effects of these drugs were also seen using MDA-MB-361 as a second model in BICA (Fig. 6b). We then examined whether EPZ-6438 (chosen over MM-102 because it has been tested in vivo28) could also promote bone colonization in vivo. Towards this end, we performed IIA injection of MCF-7 cells on animals without oestradiol supplement, which usually resulted in even more indolent bone colonization of this ER+ cell line. EPZ-6438 significantly increased bone colonization even under this oestradiol-deficient condition (Fig. 6c). Thus, it is likely that histone methylation may play an important role in cancer–niche interaction and resistance to oestrogen deprivation therapies. Because EZH2 has been considered to be a tumour-promoting gene, we hypothesized that its function could be context-dependent in human metastases. We used an EZH2 target gene signature29 as an index of EZH2 activities, and applied it to breast cancer metastases in different organs. Interestingly, a large variation was observed: bone and brain metastases express significantly lower levels of EZH2 target genes as compared to metastases in other organs (Fig. 6d). Thus, the bone microenvironment may favour reduced EZH2 activities in cancer cells. These results demonstrate the utility of BICA for discovery of unexpected effects of compounds and their target pathways.
It has long been recognized that the microenvironment plays an important role in dictating metastatic progression and modulating therapeutic responses. Both direct cell–cell crosstalk and interaction with extracellular matrix can rewire signalling network inside cancer cells, thereby modulating their behaviours under specific conditions30,31, probably through inducing epigenetic changes in cancer cells. Particularly in bone both osteoblasts and osteoclasts, as well as other resident cells, together constitute a unique cellular and molecular environment5, which likely renders metastatic cells resistant to some and vulnerable to other perturbations as compared to the same cancer cells in other milieu. A prominent example is anti-osteoclast treatment with bisphosphonate and denosumab, which have been widely used in the clinic to limit the progression of osteolytic bone metastases32. More recently, several pathways have been shown to mediate cancer–bone crosstalk, including Notch33, transforming growth factor-β (ref. 34), HIF35,36, Integrin37, Irf7 (ref. 38), VCAM1 (ref. 39) and mTOR13. These clinical and preclinical investigations highlighted the urgency of considering microenvironment when treating metastatic cancers. BICA meets this imperative need by recapitulating cancer–niche interaction in early-stage bone colonization and revealing bone-specific therapeutic responses.
Some previous studies also aimed to model cancer–bone interactions under ex vivo or in vitro settings40. One study added cancer cells to already-fragmented bone chips41,42. Others attempted to mimic one or a few aspects of the bone microenvironment by using extracellular matrix43,44, hydrogel45, man-made ceramic and composite scaffolds46, or cell-derived matrices47. BICA differs significantly from these approaches, in that it delivers cancer cells into natural bone tissue via circulation, and allows the subsequent seeding and cancer–niche interaction to occur in vivo. Because of the tight cancer–bone adherence, several important features are maintained after fragmentation, including the cellular components of the metastasis niche, the gene expression of cancer cells, growth kinetics and the specific mechanisms of cancer–niche crosstalk (Figs 1, 2, 3). This faithfulness has not been demonstrated in any of the above ex vivo models.
Co-transplantation of human fetus bone fragments and cancer cells have been demonstrated. Spontaneous bone metastases occurred preferentially to human bones over mouse bones in this model. Moreover, the cancer–bone interaction is between human tissues48. However, restricted availability of fetus bone tissue limits the wide application of this approach. Moreover, it would be difficult to apply quantitative and rapid parallel assays with spontaneous metastasis models. BICA overcomes these barriers and provides a highly complementary platform to accelerate therapeutic and mechanistic studies of bone metastasis.
In the current study BICA was primarily used to model pre-osteolytic micrometastases, although we also demonstrated its potential to investigate the onset of osteoclast activation. Perhaps because of limited bone surface area and insufficient monocyte supply, the ability of BICA to model full-fledged vicious cycle is limited. The pre-osteolytic stage corresponds to the phase when adjuvant therapies are applied in the clinic. Although adjuvant therapies are intended to target micrometastases in distant organs, the decision and choice of specific treatments has to be made based on features of primary tumours. In this study we provided three specific examples of how cancer cells in a different context may respond differently to certain drugs. While danusertib exhibited enhanced efficacies on cancer cells interacting with bone, two HMT inhibitors unexpectedly showed the opposite trend—they promoted tumour growth, specifically in the bone microenvironment. Several types of mechanisms could lead to such markedly altered responses. First, cancer–bone interaction may rewire the signalling network in cancer cells, thereby altering their responses to certain drugs. Second, some drugs may act on the microenvironment niche cells, thereby indirectly affecting cancer cells. Third, biophysical and biochemical properties of the microenvironment niche may enrich or deprive certain drugs, thereby changing the bioavailability of these drugs to cancer cells. Future studies will be needed to delineate specific mechanisms behind each drug that exhibits distinct effects on cancer cells in the bone microenvironment.
We observed that endothelial cells could persist for weeks in BICA (Supplementary Fig. 1f). Moreover, we detected dormant cancer cells adjacent to endothelial cells (Supplementary Fig. 4d). These results support that the peri-vascular niche regulates metastasis dormancy20,21. Our previous studies demonstrated that the osteogenic niche promotes cancer cell proliferation13. Thus, cellular fates of cancer cells may be influenced by their distribution or migration between different microenvironment niches. More quantitative and, ideally, real-time imaging will be needed to further pursue this hypothesis. A limitation of BICA is the lack of immune cells other than monocytes. Adaptive immunity was shown to play an important role in bone metastasis38. This limitation may be partially overcome by reconstituting some of the immune cell components in the ex vivo environment of BICA in future studies.
None of the cell lines used in this study are listed in the database of commonly misidentified cell lines maintained by ICLAC and NCBI Biosample. MCF-7, MDA-MB-231 and MDA-MB-361 were purchased from American Type Culture Collection. S.I. Abrams (National Cancer Institute) generously provided AT3 cells. For regular maintenance, cells were cultured in DMEM media supplemented with 10% fetal bovine serum (FBS). As the parallel control for BICA assay, 500 cells were seeded and then cultured in DMEM/F12 media supplemented with 2% FBS in 96-well plates. No cell line authentication was performed. Cell lines were subjected to bi-monthly tests for mycoplasma contamination.
Lentivirus transduction of tumour cells
The Fluc-GFP fusion gene was cloned into expression vector pwpt-GFP (Addgene #12255) in place of the GFP gene in the backbone. Using Xtreme Gene HP DNA Transfection Reagent (Version 08, Roche), the pwpt-Fluc-GFP vector was transfected into 293T cells with pMD2.G (Addgene #12259) and psPAX2 (Addgene #12260) to package lentivirus. Lentiviral stocks were filtered by 0.45 μm polyethersulfone membranes (VWR 28145–505). Cancer cells were incubated with Fluc-GFP lentivirus and 4 μg ml−1 polybrene for 8 h. After a 72 h culture period, successfully labelled cells were isolated by FACS sorting of GFP-positive cells.
The inducible H2B-GFP system was reported18 and used in our previous study. Briefly, the H2B-GFP fusion gene was introduced into pINDUICER22 vector49 in place of the original GFP gene. Virus generation and transduction were performed using the same procedures as described above. A unit of 1 μg ml−1 doxycycline treatment was performed for 3 days to induce the H2B-GFP protein expression in cells. The H2B-Fluc vector was modified from H2B-GFP system, which replaced the GFP gene with the Fluc gene.
PDX 4664, gifted by Dr Mike Lewis’ lab at Baylor College of Medicine, is an established PDX tumour model, which has been granted protocol exemption by the Institutional Review Board of Baylor College of Medicine for not involving human subjects.
Immunofluorescent staining was performed as previously described13. Bone or BICA pieces were collected 3 weeks after tumour cell inoculation. Sample preparation was assisted by the shared Pathology Core resource of Dan L. Duncan Cancer Center. Staining was performed using antibodies against ALP (Abcam, ab108337, 1:500), Col-I (GeneTex, GTX41286, 1:500), CTSK (Abcam, ab19027, 1:100), Osterix (Abcam, ab22552, 1:500), CD31 (Abcam, ab28364, 1:100) and N-cadherin (BD, 610920, 1:250).
Bone seeding model
The assay was performed as previously described42. Femoral heads were fragmented and aligned into the low-attachment 96-well plates with 100 μl DMEM-F12 media with 2% FBS. MCF-7 cells were seeded on top of these slices at a density of 20,000 cells per well and then incubated and traced by bioluminescence imaging for 28 days.
Extracellular matrix coating model
The assay was performed as previously described, with slight modification44. Briefly, 500 cells were plated on top of solidified Matrigel Membrane Matrix (Corning, 354234) or Col-I (BD 354236) in each well of a 96-well plate. Cells were fed once every week with DMEM-F12 media with 2% FBS and traced by bioluminescence imaging for 28 days.
3D suspension culture model
A total of 20,000 luciferase-labelled cancer cells were cultured in a low-attachment 24-well plate in DMEM/F12 media with either 2% FBS or murine basic fibroblast growth factor (20 ng ml−1, Life Technologies), as well as murine epidermal growth factor (20 ng ml−1, Life Technologies) and B27 supplement (GIBCO). Cell growth was traced by bioluminescence imaging for 24 days.
Athymic nude mice and Balb/c mice were purchased from Harlan Sprague Dawley. Osx1-GFP::Cre mice, Tie2-Cre mice and Cdh2flox mice were purchased from Jackson Laboratories (stock numbers: 006361; 004128; and 007611, respectively). These strains were intercrossed to produce experimental cohorts Osx1-GFP::Cre/Cdh2flox and Tie2-Cre/Cdh2flox mice. Mice were genotyped by PCR. To halt EGFP/Cre fusion protein expression, mice were provided with fresh drinking water containing 2 mg ml−1 doxycycline (Sigma). The 5- to 7-week-old female mice were used in all in vivo/ex vivo experiments. The strain and number of mice used for each experiment are mentioned in text and legends. All animal work was done in accordance with a protocol approved by the Baylor College of Medicine Institutional Animal Care and Use Committee. The investigator was not blinded to the group allocation during the whole experiment.
Injection and quantification of cancer cells in bone
Intra-iliac injections, mammary pad injections and IVIS imaging were performed as previously described while the data normalization was processed with slight modifications13. After injection, animals were imaged weekly using IVIS Lumina II (Advanced Molecular Vision), following the manufacturer’s recommended procedures and settings. For intra-iliac injection, we focused on bioluminescence signals at the epiphysis and metaphysis of femur and tibia other than the entire hindlimb. The acquired intensity data were divided over the day 0 signal intensity of the same animal at the same locus to yield normalized values. The intensity values were first normalized to day 0 and then subjected to statistical tests.
Spontaneous bone metastasis assay
The spontaneous bone metastasis assay was performed as previously described, with slight modifications13. Briefly, BALB/c mice were subjected to mammary fat pad injections of 1 × 105 4T1.2 cells suspended in 50% Growth Factor Reduced Matrigel Matrix. Surgical resection was used to remove the tumours after 10–11 days. Mice were then randomized into different treatment groups and closely monitored for another 2 weeks. Bioluminescence imaging was performed before mice were killed. The Student’s t-test was used to compute the P value.
Torin 1 (S2827, Selleckchem), PD98059 (A1663, ApexBio) and danusertib (A4116, ApexBio) were injected via intraperitoneal (i.p.) injection, daily, at the dosage of 6.8, 10 and 15 mg kg−1, respectively. EPZ6438 (A8221, ApexBio) was injected via i.p. injection once every 2 days at 50 mg kg−1. For antibody therapy, 4 mg kg−1 DECMA-1 (U3254; Sigma) or rat immunoglobulin G (I4131; Sigma) was injected via i.p.injection twice a week. In the experiments using MCF-7 cells, oestradiol pellets were prepared and transplanted into nude mice before cancer cell injection, according to a previously published protocol50, unless otherwise noted.
Set-up of BICA
Bone-in-culture pieces were prepared from the distal epiphysis and metaphysis of the femurs and the proximal epiphysis and metaphysis of the tibias collected from mice 30 min after receiving intra-iliac injection (Fig. 1a and Supplementary Fig. 1a). The bones were crushed with a sterilized bone plier (F.S.T. 16025–14), trimmed with micro dissecting scissor (Roboz RS-5912) and transferred to low-attachment 96-well plates by micro dissecting forceps (Roboz RS-5135) in a cell culture hood. Bone fragments derived from multiple animals were randomized and mixed in each group. Bone pieces bearing tumour cells were arranged in low-attachment 96-well plates and cultured in media comprises DMEM/F12. The concentration of FBS varied, with human at 2% and mouse at 0.5%. Medium was changed every 3–4 days, with medium being removed along the wall of wells to avoid fragment aspiration. An IVIS Lumina II machine was used for bioluminescence imaging. The bioluminescence intensity data were divided over the day 0 signal intensity of the same piece to yield normalized values. Field of view=D; Exposure time=1 min; bining=Medium; F/Stop=1 for luminescent imaging. The intensity values were first normalized to day 0 and then subjected to statistical tests.
An epigenetics compound library used for drug screening was purchased from Selleckchem (Catalogue # L1900, 128cpds, ordered in June 2015). BICA samples preloaded with MCF-7 cells were aligned in low-attachment 96-well plates with six replicates per condition. In the first screening, 68 small-molecule epigenetic modulators were selected and grouped at a concentration of 100 nM for each compound based on information provided by the vender. In the secondary screenings, single compounds were tested at 100 nM separately. The names of selected compounds and group information are provided in Supplementary Table 1. For parallel experiments in 2D cultures, MCF-7 were plated in cell culture-treated 96-well plates at a density of 500 cells in 200 μl medium per well with six replicates per condition.
RNA-seq experiment and data analysis
All tumour samples were collected 3 weeks after inoculation. After homogenization, total RNA was extracted using the Direct-zol RNA miniprep kit. The first and second strands of cDNA were prepared by SuperScript III First-Strand Synthesis System and NEBNext mRNA Second Strand Synthesis Module from at least 200 ng total RNA, for each sample. Sequencing libraries were prepared from 1 ng of purified double-stranded cDNA with the Illumina Nextera XT DNA Library Prep Kit (Illumina, San Diego, CA, USA) according to the protocol supplied by the manufacturer. Cluster generation was performed using the Illumina Nextseq 500/550 high output v2 kit and sequenced on the Illumina Nextseq 500 equipment.
RNA-seq next-generation sequencing reads derived from xenograft materials containing a mixture of human and mouse reads were separated using Xenome (version 1.0.1)51. We used the default k-mer size suggested by Xenome (-k 25).
RNA-seq next-generation sequencing reads were mapped using STAR RNA-seq aligner (version 2.4.1d)52. To improve mapping accuracy, the gene transfer format file was supplied at the genome index generation step with the command line option—sjdbOverhang 79 (ReadLength - 1) together with the genome fasta file. To make full use of the reads not uniquely mapped we used RSEM53, which applies estimation maximization to quantify gene and isoform expression. DEseq2 R package54 was used to normalize the gene/isoform expression matrix.
Single sample gene set enrichment analysis (ssGSEA) was performed according to previous studies55,56, which was used to calculate separate enrichment scores (ES) for each pairing of a sample and gene set in Molecular Signatures Database (MSigDB). ssGSEA (v7) analyses were performed using GenePattern (http://genepattern.broadinstitute.org/). This procedure is similar to GSEA. But unlike ranking the genes by comparing samples from two groups, the ssGSEA ranks the genes by their absolute expression in one sample. The ranked gene list is used to compute the ES with Empirical Cumulative Distribution Functions. And the ESgene signature=ESgenes in the signature−ESgenes not in the signature.
The 13 bone marrow reference cells were downloaded from the E-MTAB-2923 data set57. Reads were mapped and quantified using STAR and were subsequently sorted using Samtools (version 0.1.19)58. HT-seq suite59 was used. The reads count matrix was normalized using DEseq2. CIBERSORT60 was used to estimate the relative percent of 13 bone marrow cell compositions. We used 1,000 permutation and disabled quantile normalization. EZH2 signature was downloaded from MSigDB http://software.broadinstitute.org/gsea/msigdb/collections.jsp and was computed as Σ Upregulated genes−Σ Downregulated genes.
All results are presented in the form of mean±s.e.m., unless otherwise specified. Sample sizes for in vivo experiments are noted in the corresponding figures or figure legends. For in vivo experiments, sample size was determined by preliminary experiments or previous reports13. Randomization process was performed by randomly assigning animals into two separate groups after tumour inoculation, in Fig. 5e. No randomization was used in other experiments. No specific tests were conducted to test the assumption of normal distribution. Log-transformation were performed for most dot-plot graphs to achieve better visualization. Differences among growth curves and IC50 inhibition curves were assessed using repeated measure analysis of variance tests. In experiments consisting of more than two groups, the differences between means of different experimental groups were analysed using one-way analysis of variance tests, unless otherwise noted in respective legends. F-tests were performed to compare variations within different groups. Student’s t-tests were performed with the assumption of equal variation. If the data did not meet the equal variation assumption, Welch correction or non-parametric analysis was performed.
The raw data of RNA-seq results used for Fig. 1 and Supplementary Fig. 1 have been deposited to NIH Gene Expression Omnibus and assigned the accession number GSE84114. All other remaining data are available within the Article and its Supplementary Files, or available from the authors on request.
How to cite this article: Wang, H. et al. Bone-in-culture array as a platform to model early-stage bone metastases and discover anti-metastasis therapies. Nat. Commun. 8, 15045 doi: 10.1038/ncomms15045 (2017).
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Aguirre-Ghiso, J. A. Models mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7, 834–846 (2007).
Pantel, K., Alix-Panabieres, C. & Riethdorf, S. Cancer micrometastases. Nat. Rev. Clin. Oncol. 6, 339–351 (2009).
Smid, M. et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 68, 3108–3114 (2008).
Kozlow, W. & Guise, T. A. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J. Mammary Gland Biol. Neoplasia 10, 169–180 (2005).
Ell, B. & Kang, Y. SnapShot: bone metastasis. Cell 151, 690 (2012).
Boyce, B. F., Yoneda, T. & Guise, T. A. Factors regulating the growth of metastatic cancer in bone. Endocr. Relat. Cancer 6, 333–347 (1999).
Weilbaecher, K. N., Guise, T. A. & McCauley, L. K. Cancer to bone: a fatal attraction. Nat. Rev. Cancer 11, 411–425 (2011).
Mundy, G. R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584–593 (2002).
Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537–549 (2003).
Yin, J. J. et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103, 197–206 (1999).
Kakonen, S. M. et al. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J. Biol. Chem. 277, 24571–24578 (2002).
Korpal, M. et al. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15, 960–966 (2009).
Wang, H. et al. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell 27, 193–210 (2015).
Welte, T., Yu, C. & Zhang, X. H. Retrieval of disseminated tumor cells colonizing the bone in murine breast cancer metastasis models. J. Mammary Gland Biol. Neoplasia 20, 103–108 (2015).
Minn, A. J. et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J. Clin. Invest. 115, 44–55 (2005).
Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938–945 (2015).
Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189–196 (2016).
Fuchs, E. & Horsley, V. Ferreting out stem cells from their niches. Nat. Cell Biol. 13, 513–518 (2011).
Liang, Y., Yan, C. & Schor, N. F. Apoptosis in the absence of caspase 3. Oncogene 20, 6570–6578 (2001).
Price, T. T. et al. Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone. Sci. Transl. Med. 8, 340ra373 (2016).
Ghajar, C. M. et al. The perivascular niche regulates breast tumour dormancy. Nat. Cell Biol. 15, 807–817 (2013).
Vader, G. & Lens, S. M. The Aurora kinase family in cell division and cancer. Biochim. Biophys. Acta 1786, 60–72 (2008).
Fancelli, D. et al. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J. Med. Chem. 49, 7247–7251 (2006).
Meulenbeld, H. J. et al. Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU Int. 111, 44–52 (2013).
Eckhardt, B. L. et al. Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol. Cancer Res. 3, 1–13 (2005).
Knutson, S. K. et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol. Cancer Ther. 13, 842–854 (2014).
Karatas, H. et al. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction. J. Am. Chem. Soc. 135, 669–682 (2013).
Knutson, S. K. et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl Acad. Sci. USA 110, 7922–7927 (2013).
Lu, C. et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 18, 185–197 (2010).
Oskarsson, T., Batlle, E. & Massague, J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 14, 306–321 (2014).
Correia, A. L. & Bissell, M. J. The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist. Updat. 15, 39–49 (2012).
Suva, L. J., Washam, C., Nicholas, R. W. & Griffin, R. J. Bone metastasis: mechanisms and therapeutic opportunities. Nat. Rev. Endocrinol. 7, 208–218 (2011).
Sethi, N., Dai, X., Winter, C. G. & Kang, Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 19, 192–205 (2011).
Buijs, J. T., Stayrook, K. R. & Guise, T. A. TGF-beta in the bone microenvironment: role in breast cancer metastases. Cancer Microenviron. 4, 261–281 (2011).
Wu, C. et al. Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerin. Genes Dev. 29, 817–831 (2015).
Dunn, L. K. et al. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS ONE 4, e6896 (2009).
Schneider, J. G., Amend, S. R. & Weilbaecher, K. N. Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone 48, 54–65 (2011).
Bidwell, B. N. et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 18, 1224–1231 (2012).
Lu, X. et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell 20, 701–714 (2011).
Taubenberger, A. V. In vitro microenvironments to study breast cancer bone colonisation. Adv. Drug Deliv. Rev. 79–80, 135–144 (2014).
Krawetz, R., Wu, Y. E., Rancourt, D. E. & Matyas, J. Osteoblasts suppress high bone turnover caused by osteolytic breast cancer in-vitro. Exp. Cell Res. 315, 2333–2342 (2009).
Templeton, Z. S. et al. Methods for culturing human femur tissue explants to study breast cancer cell colonization of the metastatic niche. J. Vis. Exp. e52656 http://dx.doi.org/10.3791/52656 (2015).
Sloan, E. K. et al. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res. 8, R20 (2006).
Ganapathy, V. et al. Targeting the transforming growth factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol. Cancer 9, 122 (2010).
Cox, R. F., Jenkinson, A., Pohl, K., O’Brien, F. J. & Morgan, M. P. Osteomimicry of mammary adenocarcinoma cells in vitro; increased expression of bone matrix proteins and proliferation within a 3D collagen environment. PLoS ONE 7, e41679 (2012).
Pathi, S. P., Kowalczewski, C., Tadipatri, R. & Fischbach, C. A novel 3-D mineralized tumor model to study breast cancer bone metastasis. PLoS ONE 5, e8849 (2010).
Taubenberger, A. V., Quent, V. M., Thibaudeau, L., Clements, J. A. & Hutmacher, D. W. Delineating breast cancer cell interactions with engineered bone microenvironments. J. Bone Miner. Res. 28, 1399–1411 (2013).
Kuperwasser, C. et al. A mouse model of human breast cancer metastasis to human bone. Cancer Res. 65, 6130–6138 (2005).
Meerbrey, K. L. et al. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc. Natl Acad. Sci. USA 108, 3665–3670 (2011).
Robinson, S. P. & Jordan, V. C. Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse. Cancer Res. 49, 1758–1762 (1989).
Conway, T. et al. Xenome—a tool for classifying reads from xenograft samples. Bioinformatics 28, i172–i178 (2012).
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108–112 (2009).
Reiner, A., Yekutieli, D. & Benjamini, Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19, 368–375 (2003).
Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).
van der Pluijm, G. et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J. Clin. Invest. 98, 698–705 (1996).
We thank D. Weiss and Zhang Laboratory members for helpful input. We also thank Dr Abrams, S. for generously providing the AT3 cell line, and Dr Lewis, M.T. for providing the PDX4664 model. X.H.-F.Z. is supported by the US Department of Defense DAMD W81XWH-16-1-0073 (Era of Hope Scholarship), NCI CA183878, Breast Cancer Research Foundation, Susan G. Komen CCR14298445 and McNair Medical Institute. H.W. is supported by the US Department of Defense DAMD W81XWH-13-1-0296. This work was also made possible by the CyVerse Collaborative, funded by the NSF (No. DBI-0735191). We also acknowledge the Integrated Microscopy Core at Baylor College of Medicine with funding from the NIH (HD007495, DK56338 and CA125123), the Pathology Core of Lester and Sue Smith Breast Center, the Dan L. Duncan Cancer Center and the John S. Dunn Gulf Coast Consortium for Chemical Genomics.
The authors declare no competing financial interests.
About this article
Cite this article
Wang, H., Tian, L., Goldstein, A. et al. Bone-in-culture array as a platform to model early-stage bone metastases and discover anti-metastasis therapies. Nat Commun 8, 15045 (2017). https://doi.org/10.1038/ncomms15045
Molecular Cancer (2021)
npj Breast Cancer (2020)
Meeting report: Metastasis Research Society (MRS) 17th Biennial conference and associated Young Investigator Satellite Meeting (YISM) on cancer metastasis
Clinical & Experimental Metastasis (2019)
Current Molecular Biology Reports (2019)